These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 15482128)

  • 1. A designer drug against influenza: the NA inhibitor oseltamivir (Tamiflu).
    Oxford JS; Mann A; Lambkin R
    Expert Rev Anti Infect Ther; 2003 Aug; 1(2):337-42. PubMed ID: 15482128
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Early therapy with the neuraminidase inhibitor oseltamivir maximizes its efficacy in influenza treatment.
    Gillissen A; Höffken G
    Med Microbiol Immunol; 2002 Dec; 191(3-4):165-8. PubMed ID: 12458353
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neuraminidase inhibitor susceptibility network position statement: antiviral resistance in influenza A/H5N1 viruses.
    Hayden F; Klimov A; Tashiro M; Hay A; Monto A; McKimm-Breschkin J; Macken C; Hampson A; Webster RG; Amyard M; Zambon M
    Antivir Ther; 2005; 10(8):873-7. PubMed ID: 16430192
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antiviral drugs in influenza: an adjunct to vaccination in some situations.
    Prescrire Int; 2006 Feb; 15(81):21-30. PubMed ID: 16548114
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Neuraminidase inhibitors oseltamivir and zanamivir: new means of defence against influenza].
    de Jong JC; Beyer WE; Rimmelzwaan GF; Fouchier RA; Osterhaus AD
    Ned Tijdschr Geneeskd; 2004 Jan; 148(2):73-9. PubMed ID: 14753128
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Insights from investigating the interaction of oseltamivir (Tamiflu) with neuraminidase of the 2009 H1N1 swine flu virus.
    Wang SQ; Du QS; Huang RB; Zhang DW; Chou KC
    Biochem Biophys Res Commun; 2009 Aug; 386(3):432-6. PubMed ID: 19523442
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anti-influenza drugs: the development of sialidase inhibitors.
    von Itzstein M; Thomson R
    Handb Exp Pharmacol; 2009; (189):111-54. PubMed ID: 19048199
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antiviral management of seasonal and pandemic influenza.
    Hayden FG; Pavia AT
    J Infect Dis; 2006 Nov; 194 Suppl 2():S119-26. PubMed ID: 17163384
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oseltamivir (Tamiflu) and its potential for use in the event of an influenza pandemic.
    Ward P; Small I; Smith J; Suter P; Dutkowski R
    J Antimicrob Chemother; 2005 Feb; 55 Suppl 1():i5-i21. PubMed ID: 15709056
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Epidemiology, clinical picture, prevention and treatment of Avian influenza].
    Angelava NA; Angelava AV
    Georgian Med News; 2006 Feb; (131):69-76. PubMed ID: 16575138
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [The threatening influenza pandemic: a national store ofoseltamivir is a waste of money].
    Bonneux L
    Ned Tijdschr Geneeskd; 2005 Jul; 149(29):1619. PubMed ID: 16078769
    [TBL] [Abstract][Full Text] [Related]  

  • 12. On the structure-based design of novel inhibitors of H5N1 influenza A virus neuraminidase (NA).
    Mitrasinovic PM
    Biophys Chem; 2009 Mar; 140(1-3):35-8. PubMed ID: 19117662
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neuraminidase inhibitors and their role in avian and pandemic influenza.
    Crusat M; de Jong MD
    Antivir Ther; 2007; 12(4 Pt B):593-602. PubMed ID: 17944267
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Resistance to anti-influenza drugs: adamantanes and neuraminidase inhibitors.
    Hurt AC; Ho HT; Barr I
    Expert Rev Anti Infect Ther; 2006 Oct; 4(5):795-805. PubMed ID: 17140356
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Emergence of drug-resistant influenza virus: population dynamical considerations.
    Regoes RR; Bonhoeffer S
    Science; 2006 Apr; 312(5772):389-91. PubMed ID: 16627735
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative activities of oseltamivir and A-322278 in immunocompetent and immunocompromised murine models of influenza virus infection.
    Ison MG; Mishin VP; Braciale TJ; Hayden FG; Gubareva LV
    J Infect Dis; 2006 Mar; 193(6):765-72. PubMed ID: 16479509
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Function of neuraminidase of influenza virus and anti influenza compounds by its inhibition].
    Yamashita M
    Tanpakushitsu Kakusan Koso; 2009 Aug; 54(10):1284-91. PubMed ID: 19663256
    [No Abstract]   [Full Text] [Related]  

  • 18. Synthesis of influenza neuraminidase inhibitors.
    Abdel-Magid AF; Maryanoff CA; Mehrman SJ
    Curr Opin Drug Discov Devel; 2001 Nov; 4(6):776-91. PubMed ID: 11899618
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Complexity in influenza virus targeted drug design: interaction with human sialidases.
    Chavas LM; Kato R; Suzuki N; von Itzstein M; Mann MC; Thomson RJ; Dyason JC; McKimm-Breschkin J; Fusi P; Tringali C; Venerando B; Tettamanti G; Monti E; Wakatsuki S
    J Med Chem; 2010 Apr; 53(7):2998-3002. PubMed ID: 20222714
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of antiviral treatment on the outcome of secondary bacterial pneumonia after influenza.
    McCullers JA
    J Infect Dis; 2004 Aug; 190(3):519-26. PubMed ID: 15243927
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.